HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
4- amino- 8- (ribofuranosylamino)pyrimido(5,4- d)pyrimidine- 5'- phosphate
structure given in first source; RN given refers to (beta-D)-isomer
Also Known As:
APP-MP
Networked:
1
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrimidines: 510
Pyrimidine Nucleotides: 48
4-amino-8-(ribofuranosylamino)pyrimido(5,4-d)pyrimidine-5'-phosphate: 1
Nucleic Acids, Nucleotides, and Nucleosides: 1
Nucleotides: 15763
Pyrimidine Nucleotides: 48
4-amino-8-(ribofuranosylamino)pyrimido(5,4-d)pyrimidine-5'-phosphate: 1
Related Diseases
1.
Experimental Liver Neoplasms
08/01/1993 - "
This result was consistent with APP-MP acting as an inhibitor of 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase, a hypothesis that was confirmed by preparing PRPP synthetase from Novikoff hepatoma cells; APP-MP was a noncompetitive inhibitor, with a Ki of 0.43 mM. APP-MP was found to accumulate in APP-treated cells to a concentration of almost 3 mM. The relevance of PRPP synthetase inhibition to the cytotoxic mechanism of APP is indicated by the fact that depletion of the PRPP pool was seen as early as 15 min after treatment, before any change was apparent in cellular levels of ATP or UTP.
"
Related Drugs and Biologics
1.
Uridine Triphosphate (UTP)
2.
Ribose-Phosphate Pyrophosphokinase (Phosphoribosyl Pyrophosphate Synthetase)
3.
Adenosine Triphosphate (ATP)
Related Therapies and Procedures
1.
Aftercare (After-Treatment)